parkinson's disease triple agonist glp-1 gip glucagon clinical trial Diabetes, obesity, and possible actions of Targeting Metabolic Dysfunction in Parkinson's

A reminder that their story doesnt start in Hollywood

This innovative oral GLP-1 is a small molecule medication that, unlike the Wegovy pill, doesnt require that you take it on an empty stomach.

National Taiwan University researchers highlight the benefits of GLP-1 receptor agonists (GLP-1 RAs) in reducing mortality and severe cardiovascular and renal outcomes for diabetic patients with acute kidney disease (AKD)

Glucagon-like peptide-1 (GLP-1) is an incretin peptide hormone mainly secreted by enteroendocrine intestinal L-cells

For best results, we recommend 3-6 months of consistent daily use

Diabetic kidney disease, a common complication in patients with type 2 diabetes mellitus, is